On December 9, 2025, Terns Pharmaceuticals, Inc. entered into an underwriting agreement for a public offering of 16,250,000 shares of its common stock. The underwriters were granted an option to purchase an additional 2,437,500 shares, which they exercised in full on December 10, 2025. This offering is aimed at strengthening the company's financial position and funding its ongoing development activities
Who to call at Terns Pharmaceuticals, and when
A new round usually means Terns Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Terns Pharmaceuticals raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Terns Pharmaceuticals, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Terns Pharmaceuticals
Location
Foster City, California, United States
About
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH. Terns’ pipeline includes three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-β agonist, and a preclinical GIPR modulator program. For more information, please visit: www.ternspharma.com.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Terns Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Foster CityBiotechnologyHealthcareTherapeuticsPharmaceuticalBiopharma